Bevacizumab in the Treatment of Glioblastoma: Is There an Optimal Dose or Schedule?

doi 10.2174/978160805132811001010054
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BENTHAM SCIENCE PUBLISHERS

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy